A decade of clinical trials reveals big pharma is still recycling old drugs for Parkinson's

A major scientific review examining clinical trials registered across Europe and the United States over the past decade reveals that whilst research into Parkinson's has expanded significantly, genuinely novel medical breakthroughs remain surprisingly scarce. The team of researchers analysed nearly 1,900 therapeutic studies to understand where pharmaceutical investment and clinical efforts are truly heading. Their findings show that the pipeline remains heavily dominated by traditional approaches. Most commercial drug trials continue to focus on dopamine. While dopamine replacement therapies and receptor agonists provide invaluable support for daily movement, they largely tweak formulations of medicines that have existed for generations rather than offering fundamentally new ways to manage the underlying condition. Movement symptoms, especially predictable changes in mobility throughout the day, still soak up 45% of commercial research objectives. By contrast, non motor symptoms receive only 8% of industry attention. Challenges such as sleep disruption, fatigue, thinking changes, and mood disturbances often shape daily life far more profoundly than physical stiffness or tremor, yet they remain consistently overlooked by major drug development programmes. The review also points out that slowing down or halting the progression of Parkinson's continues to be an elusive target. Encouragingly, scientific interest is beginning to broaden. Researchers recorded growing exploration into clearing toxic protein build ups, alongside innovative cell and gene therapies, which together accounted for nearly 1 in 5 experimental approaches. Academic centres are also stepping in to bridge critical practical gaps, driving trials into non drug interventions, specialised devices, and physical routines that support long term well being. The study serves as an urgent call to reshape the future of research. For real innovation to reach people who need it, drug discovery must move beyond modest modifications to old remedies and focus squarely on whole body symptoms and true disease modifying solutions.